ClinicalTrials.gg

TargetBeta

STEAP2

STEAP2 metalloreductase · also IPCA-1, STAMP1, STMP, PCANAP1 · STEAP family

6 programs in company-led studies act on STEAP2, from 1 company: 0 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
STEAP2-targeting Radioconjugate AZD2287ruleAstraZenecaphase 222 running–NCIt
Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621AstraZenecaphase 211 runningCD3E, CD8Aa judged reading
Anti-STEAP2/Exatecan Antibody-drug Conjugate AZD0516AstraZenecaphase 211 running–a judged reading
Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754AstraZenecaphase 211 running–a judged reading
AZD8359ruleAstraZenecaphase 211 running–the studies' text
Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284AstraZenecaphase 111 running–a judged reading

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.